Zentalis Pharmaceuticals Inc
ZNTL
ISIN null / Valor 53183848
Zentalis Pharmaceuticals Inc
UMushroom community rating:
About company
Zentalis Pharmaceuticals is a U.S.-based, clinical-stage biopharmaceutical company focused on developing orally administered small-molecule oncology therapeutics; it advances targeted agents that interfere with cancer-specific cell cycle and transcriptional processes and evaluates those candidates in early‑phase trials across solid tumors and hematologic malignancies. Its pipeline has centered on programs such as a PLK1 inhibitor and a selective CDK2 inhibitor, with development directed at identifying biomarker-defined patient populations rather than marketing a commercial product at this time. The company funds operations through public markets and collaborations while seeking regulatory pathways to bring any successful candidates to later‑stage trials and eventual approval.
Summarized from source with an LLMView SourceSector: TechnologyKey figures
Performance
Volatility
189 M
Market cap (USD)
529,026
Daily traded volume (Shares)
3.07 / 2.89
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
